Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03473756
Recruitment Status : Recruiting
First Posted : March 22, 2018
Last Update Posted : September 22, 2020
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma. The study comprises two separate parts: Phase 1b (Part A) and Phase 2 (Part B).The study parts differ in design, objectives and treatment.

The primary objectives of this Phase 1b study (Part A) are to determine the safety, tolerability,RP2D and pharmacokinetics of rogaratinib in combination with atezolizumab in these patients.

The primary objective of the Part B is to compare progression-free survival (PFS) according to RECIST v1.1 of rogaratinib in combination with atezolizumab over placebo in combination with atezolizumab in untreated patients with FGFR-positive locally advanced or metastatic urothelial carcinoma.

Of note, patients who participate in Part A are not allowed to participate in Part B.

Part B will be initiated once the data from Part A supports continuation of the study, even if this occurs prior to primary completion of Part A. The sponsor may decide not to continue the study as a whole after completion of Part A if the data do not support further development.


Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Drug: Rogaratinib (BAY1163877) Drug: Atezolizumab Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: There is masking only in the Part B. Part A is open-label.
Primary Purpose: Treatment
Official Title: An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma
Actual Study Start Date : May 15, 2018
Estimated Primary Completion Date : March 18, 2024
Estimated Study Completion Date : September 4, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rogaratinib + Atezolizumab in Part A

Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.

Patients will receive rogaratinib plus atezolizumab combination treatment.

Drug: Rogaratinib (BAY1163877)

Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.

Part B:Rogaratinib will be administered orally b.i.d. at the RP2D that was selected in Part A of Study 19131 on all 21 days in each cycle until centrally confirmed radiological disease progression, unacceptable toxicity or consent withdrawal


Drug: Atezolizumab
Part A & Part B: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.

Placebo Comparator: Placebo + Atezolizumab
Part B:Patients will receive placebo in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Drug: Atezolizumab
Part A & Part B: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.

Drug: Placebo
Part B: Rogaratinib matching placebo will be administered orally b.i.d. at the RP2D that was selected in Part A of Study 19131 on all 21 days in each cycle until centrally confirmed radiological disease progression, unacceptable toxicity or consent withdrawal

Experimental: Rogaratinib + Atezolizumab in Part B
Part B:Patients will receive rogaratinib in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Drug: Rogaratinib (BAY1163877)

Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.

Part B:Rogaratinib will be administered orally b.i.d. at the RP2D that was selected in Part A of Study 19131 on all 21 days in each cycle until centrally confirmed radiological disease progression, unacceptable toxicity or consent withdrawal


Drug: Atezolizumab
Part A & Part B: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.




Primary Outcome Measures :
  1. Number of subjects with Dose-limiting toxicities(DLTs) in Part A [ Time Frame: Up to 21 days ]
    A DLT is defined as any of the hematological, non-hematological or other TEAEs occurring during Cycle 1 and regarded by the investigators and/or sponsor to be related to rogaratinib or atezolizumab. The CTCAE v 4.03 will be used to assess toxicities / adverse events.

  2. Number of subjects with treatment-emergent adverse events (TEAEs) in Part A [ Time Frame: Up to 5 months ]
    Part A

  3. Number of subjects with drug-related TEAEs in Part A [ Time Frame: Up to 5 months ]
    Part A

  4. Number of subjects with treatment-emergent serious adverse events(TESAEs) in Part A [ Time Frame: Up to 5 months ]
    Part A

  5. Progression Free Survival(PFS) [ Time Frame: Up to 25 months ]

    Part B Progression-free survival (PFS) is defined as the time (days) from randomization to date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented. The actual date that the tumor scan was performed will be used for this calculation. If a tumor assessment is performed over more than one day (e.g. scans for chest and abdomen done on different days for the same evaluation), the earliest date will be used for the calculation of PFS. For patients without documented radiological or clinical progression or death at the time of analysis, PFS will be censored at the last actual visit date of tumor evaluation.

    The primary analysis of PFS will be based on assessment by independent central review.



Secondary Outcome Measures :
  1. Objective Response Rate(ORR) in Part A [ Time Frame: Up to 5 months ]

    Part A:Objective response rate (ORR) is defined as the percentage of patients with complete response (CR) or partial response (PR). Patients for whom best overall tumor response is not CR or PR, as well as patients without any post-baseline tumor assessment will be considered non-responders.

    For all patients, the best overall tumor response will be determined locally by investigators using the RECIST criteria (v1.1).


  2. Maximal plasma concentration (Cmax) of rogaratinib in Part A [ Time Frame: At cycle 1 Day 1 ]
    Part A

  3. Area under the curve(0-8) (AUC(0-8)) of rogaratinib in Part A [ Time Frame: At cycle 1 Day 1 ]
    Part A

  4. Disease Control Rate(DCR) in Part B [ Time Frame: Up to 25 months ]
    Part B:Disease control rate (DCR) is defined as the percentage of patients, whose overall best response was not progressive disease (i.e. CR, PR, SD or Non CR/Non PD).

  5. Duration of Response(DOR) in Part B [ Time Frame: Up to 25 months ]
    Part B:Duration of response (DOR) (for PR and CR) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented). DOR will be defined for responders only, i.e. patients with a CR or PR.

  6. Overall Survival(OS) in Part B [ Time Frame: Up to 25 months ]
    Part B:Overall survival (OS) is defined as the time from randomization to death due to any cause. Patients alive at the date of data cut-off for analysis will be censored at the last date known to be alive.

  7. Objective Response Rate (ORR) in Part B [ Time Frame: Up to 25 months ]
  8. Concentrations for rogaratinib in Part B [ Time Frame: Cycle 1 Day 1(C1D1), C2D1, C3D1, C4D1, C5D1 ]
    Part B

  9. Concentrations for atezolizumab in Part B [ Time Frame: C1D1, C1D15 ]
    Part B

  10. Number of subjects with treatment-emergent adverse events (TEAEs) in Part B [ Time Frame: Up to 25 months ]
    Part B

  11. Number of subjects with drug-related TEAEs in Part B [ Time Frame: Up to 25 months ]
    Part B

  12. Number of subjects with treatment-emergent serious adverse events(TESAEs) in Part B [ Time Frame: Up to 25 months ]
    Part B

  13. Number of subjects with significant change in vital signs, physical finding and clinical laboratory results [ Time Frame: Up to 25 months ]
    Part B



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Existence of archival or fresh tumor biopsy specimen for FGFR1/3 mRNA expression testing
  • High FGFR1 or 3 mRNA expression levels (RNAscope score of 3+ or 4+) in archival or fresh tumor biopsy specimen
  • Documented locally advanced (T4, any N; or any T, N2-3) or metastatic urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra, meeting all of the following criteria:
  • No prior systemic treatment for locally advanced or metastatic urothelial carcinoma. For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval > 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment-naïve in the metastatic setting. Prior local intra-vesical chemotherapy or prior local immunotherapy is allowed if completed at least 4 weeks before the first study drug administration. Regionally available standard of care options must be considered for all patients.
  • Ineligibility for cisplatin-based chemotherapy as defined by any one of the following criteria:

    • Impaired renal function (GFR > 30 but < 60 mL/min/1.73 m2) according to the modification of diet in renal disease (MDRD) abbreviated formula
    • A Hearing loss (measured by audiometry) of > 25 dB at two contiguous test frequencies in at least one ear.
    • Grade ≥ 2 peripheral neuropathy (i.e. sensory alteration or paresthesia including tingling)
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.

Exlusion criteria:

  • Active symptomatic or untreated brain metastases as determined by CT or MRI evaluation during screening and prior radiographic assessment.
  • History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
  • History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:

    • Congestive heart failure (CHF) NYHA Class 2 or greater, unstable angina (symptoms of angina at rest) or
    • New-onset angina (within last 3 months before the first study drug administration)
    • Myocardial infarction (MI) within past 6 months before the first study drug administration
    • Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.
  • Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or known left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
  • Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
  • Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis, paraneoplastic hypercalcemia).
  • Concomitant therapies that are known to increase serum calcium or phosphate levels (i.e. antacids, phosphate-containing laxatives oral/rectal, potassium phosphate) and that cannot be discontinued or switched to a different medication before the first study drug administration
  • Treatment with systemic corticosteroids or other systemic immunosuppressant medications within 2 weeks before the first study drug administration, or anticipated requirement for systemic immunosuppressive medications during the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03473756


Contacts
Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+) 1-888-8422937 clinical-trials-contact@bayer.com

Locations
Show Show 33 study locations
Sponsors and Collaborators
Bayer
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT03473756    
Other Study ID Numbers: 19131
2017-001483-38 ( EudraCT Number )
First Posted: March 22, 2018    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
Locally advanced or metastatic urothelial carcinoma
Bladder cancer
Checkpoint inhibition
FGFR inhibition
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Atezolizumab
Antineoplastic Agents